3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Unknown
1
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Conditions
Prostatic Neoplasms
7
Polycystic Ovary Syndrome
5
Ovarian Hyperstimulation Syndrome
3
Infertility
3
Breast Neoplasms
2
The Neoadjuvant Therapy
1
Sarcoma, Ewing
1
Sarcoma
1
Osteosarcoma
1
Neoplasms
1
Neoadjuvant Therapy \ High Risk Prostate Cancer \ Docetaxel
1
Lymphoma
1
Helping Behavior
1
Interventions
Cyclophosphamide
37
Etoposide
25
Vincristine
24
Cytarabine
21
Doxorubicin
19
Rituximab
17
Radiotherapy
17
Peripheral Blood Stem Cell Transplantation
16
Melphalan
16
Prednisolone
14
Methotrexate
14
Filgrastim
13
fludarabine phosphate
11
Prednisone
11
Dexamethasone
11
Carmustine
9
Bleomycin
9
pegylated granulocyte colony-stimulating factor
8
Cyclosporine
8
Busulfan
8
fludarabine
7
Ifosfamide
7
Cisplatin
7
sargramostim
6
Vinblastine
6
Mitoxantrone
6
Methylprednisolone
6
Gemcitabine
6
Chlorambucil
6
Antilymphocyte Serum
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Lymphoma
×
Triptorelin Pamoate
×
Clear all
NCT02856048
2019-12-17
PRESOV
Assistance Publique - Hôpitaux de Paris
Phase 2/3
Unknown
11 enrolled